Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.46 -2.4%	$2.09	$0.80 ▼ $3.42	$103.53M	-0.88	188,526 shs	49,443 shs
BMEA Biomea Fusion	$1.80 +0.8%	$1.82	$1.29 ▼ $13.07	$105.93M	-0.14	739,436 shs	222,474 shs
COYA Coya Therapeutics	$6.59 +7.2%	$6.01	$4.65 ▼ $10.24	$102.86M	0.26	57,105 shs	109,282 shs
RVPH Reviva Pharmaceuticals	$0.52 +0.2%	$0.48	$0.30 ▼ $4.28	$24.92M	-0.05	2.79 million shs	1.49 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	+1.61%	+5.00%	+40.00%	+127.03%	+27.28%
BMEA Biomea Fusion	+3.49%	+3.49%	-2.73%	+22.76%	-69.68%
COYA Coya Therapeutics	+3.54%	-0.81%	+6.40%	+7.71%	+8.85%
RVPH Reviva Pharmaceuticals	-2.74%	+12.87%	+31.34%	-50.55%	-54.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.2468 of 5 stars	3.3	3.0	2.6	1.7	0.0
BMEA Biomea Fusion	3.4512 of 5 stars	4.6	3.0	1.0	2.5	0.6
COYA Coya Therapeutics	1.8988 of 5 stars	3.5	2.0	2.4	0.8	0.0
RVPH Reviva Pharmaceuticals	2.8521 of 5 stars	3.6	1.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	123.58% Upside
BMEA Biomea Fusion	3.17	Buy	$16.80	835.93% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	150.38% Upside
RVPH Reviva Pharmaceuticals	3.13	Buy	$7.17	1,278.21% Upside

Current Analyst Ratings Breakdown

Latest RVPH, BMEA, COYA, and ANEB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	RVPH Reviva Pharmaceuticals	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $3.00
8/18/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
COYA Coya Therapeutics	$3.55M	31.06	N/A	N/A	$1.69 per share	3.90
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	0.00	∞	N/A	N/A	-90.11%	-84.53%	9/24/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.03	0.00	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	11/5/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	N/A	N/A	N/A	N/A	N/A	-259.17%	N/A

Latest RVPH, BMEA, COYA, and ANEB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
BMEA Biomea Fusion	N/A	3.68	3.68
COYA Coya Therapeutics	N/A	7.43	7.43
RVPH Reviva Pharmaceuticals	N/A	0.90	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BMEA Biomea Fusion	96.72%
COYA Coya Therapeutics	39.75%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BMEA Biomea Fusion	18.42%
COYA Coya Therapeutics	12.00%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

RVPH, BMEA, COYA, and ANEB Headlines

Recent News About These Companies

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives "Buy" Rating from D. Boral Capital

August 20 at 2:19 AM | americanbankingnews.com

RVPH: There May Be A Faster Way

August 19 at 7:56 PM | finance.yahoo.com

Reviva Pharmaceuticals Advances Schizophrenia Treatment

August 18 at 12:30 AM | tipranks.com

Maxim Group Cuts Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $2.00

August 18 at 2:06 AM | americanbankingnews.com

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

August 18 at 2:33 AM | msn.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

August 16, 2025 | americanbankingnews.com

Reviva Narrows Loss 23% in Fiscal Q2

August 14, 2025 | aol.comA

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Reviva Pharmaceuticals (RVPH) Expected to Announce Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH, BMEA, COYA, and ANEB Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.46 -0.06 (-2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.45 -0.01 (-0.41%)

As of 06:28 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Biomea Fusion NASDAQ:BMEA

$1.80 +0.02 (+0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 0.00 (0.00%)

As of 07:41 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Coya Therapeutics NASDAQ:COYA

$6.59 +0.44 (+7.15%)

Closing price 04:00 PM Eastern

Extended Trading

$6.67 +0.08 (+1.20%)

As of 07:56 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.52 +0.00 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 0.00 (0.00%)

As of 07:41 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time